- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/38 - Drugs for disorders of the endocrine system of the suprarenal hormones
Patent holdings for IPC class A61P 5/38
Total number of patents in this class: 130
10-year publication summary
|
1
|
6
|
4
|
11
|
16
|
10
|
18
|
13
|
10
|
11
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Corcept Therapeutics, Inc. | 370 |
22 |
| Spruce Biosciences, Inc. | 49 |
14 |
| Neurocrine Biosciences, Inc. | 462 |
7 |
| Mitsubishi Tanabe Pharma Corporation | 398 |
4 |
| Crinetics Pharmaceuticals, Inc. | 132 |
4 |
| National University Corporation Tokai National Higher Education and Research System | 877 |
4 |
| Sanofi | 4320 |
3 |
| HBM Alpha Therapeutics, Inc. | 6 |
3 |
| Sumitomo Chemical Company, Limited | 8963 |
2 |
| The Regents of the University of Michigan | 5012 |
2 |
| The Brigham and Women's Hospital, Inc. | 2289 |
2 |
| Crossject | 115 |
2 |
| Kyungpook National University Industry-Academic Cooperation Foundation | 1240 |
2 |
| Fujita Academy | 84 |
2 |
| Strongbridge Dublin Limited | 11 |
2 |
| Damian Pharma AG | 20 |
2 |
| Scohia Pharma, Inc. | 23 |
2 |
| Cincor Pharma, Inc. | 23 |
2 |
| Limited Liability Company «genetic Technologies» (llc «genetic Technologies») | 2 |
2 |
| Novartis AG | 10178 |
1 |
| Other owners | 46 |